Ranolazine reduces oxygen consumption by inhibiting the late inward sodium current in cardiac cells and reducing intracellular calcium overload. This will result in a decrease in left ventricular diastolic tension. As a result, coronary blood flow improved.
Ranolazine's action does not depend upon reductions in heart rate or blood pressure.
Cellular calcium overload contributes to the impairment of the left ventricle due to myocardial ischemia. Ranolazine helps to prevent calcium overload in this process.
Ranolazine can be used as a second-line agent for refractory angina alongside other common anti-angina drugs such as beta-blockers, calcium channel blockers, and or nitrites. It is used to treat chronic angina.
Ranolazine can cause dose-dependent dizziness. It is the most common side effect which can present in more than 4% of treated patients.
Ranolazine can cause dose-dependent headaches. It is the most common side effect which can present in more than 4% of treated patients.
Ranolazine can cause dose-dependent nausea and vomiting.
Constipation can occur as a side effect of Ranolazine.
QT prolongation can occur in patients taking Ranolazine. It is associated with a high dose, the use of QT prolongation drugs, extended exposure, personal or family history of congenital long QT syndrome, and potassium channel variants causing a prolonged QT interval.
Picmonic's rapid review multiple-choice quiz allows you to assess your knowledge.
*Average video play time: 2-3 minutes
Unforgettable characters with concise but impactful videos (2-4 min each)